Category: Zacks Small Cap Research

123455830 / 578 POSTS
By Lisa ThompsonNASDAQ:MOGOREAD THE FULL MOGO RESEARCH REPORTMogo (NASDAQ:MOGO) reported revenues for the second quarter of 2019 of $16.4 million versus $15.4 million a year ago up 6%. Revenues from subscriptions and services were $8.2 million versus ...
By David Bautz, PhDNASDAQ:SNGXREAD THE FULL SNGX RESEARCH REPORTBusiness UpdateMultiple Important Near-Term CatalystsSoligenix, Inc. (NASDAQ:SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and ...
By Brian Marckx, CFANASDAQ:CTSO | NYSE:FMSREAD THE FULL CTSO RESEARCH REPORTRecent Highlights‣ Record Revenue, Margins: Q2 set records on Product Revenue, Total Revenue, Direct Sales and Product Margin. And this is despite lack of significant orderin ...
By David Bautz, PhDNASDAQ:INMBREAD THE FULL INMB RESEARCH REPORTBusiness UpdatePositive Preliminary Data from INB03 Phase 1 Clinical TrialOn August 5, 2019, INmune Bio, Inc. (NASDAQ:INMB) announced positive preliminary data from the ongoing Phase 1 c ...
Few things matter more to thousands of small-cap companies than trading volume. And yet, few aspects are more misunderstood. Here are five critical concepts about trading volume that small-cap officers and directors routinely misunders ...
By David Bautz, PhDNYSE:OGENREAD THE FULL OGEN RESEARCH REPORTBusiness UpdateEnrollment of Phase 2 Trial of AG013 to Complete in 4Q19Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 i ...
By Brian Marckx, CFANASDAQ:DRRXREAD THE FULL DRRX RESEARCH REPORTQ2 Financial Results and Operational UpdateDurect Corp (NASDAQ:DRRX) reported financial results for their second quarter ending June 30th and provided a pipeline development update. Maj ...
By David Bautz, PhDTSX:MDNA.TO | OTC:MDNAFREAD THE FULL MDNA.TO RESEARCH REPORTBusiness UpdateMedicenna Therapeutics Corp. (TSX:MDNA) (OTC:MDNAF) is a clinical stage immuno-oncology company developing novel versions of the cytokines Interleukin (IL) ...
By Lisa ThompsonNASDAQ:NETEREAD THE FULL NETE RESEARCH REPORTIn the second quarter of 2019, Net Element (NASDAQ:NETE) beat both our top and bottom line non-GAAP numbers. Total revenues were flat with last year; North American sales increased 9.1% yea ...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTRevenues beat expectations as Crackle turned out contributing more than previously thought despite being part of Chicken Soup for the Soul Entertainment (NASDAQ:CSSE) for only half the quar ...
123455830 / 578 POSTS